Neuphoria Therapeutics Inc. entered into a definitive merger agreement with Scancell Holdings plc on July 23, 2026. Under the terms, Neuphoria will become an indirect wholly owned subsidiary of Scancell, with Neuphoria stockholders expected to own approximately 13.7% of the combined company's ordinary share capital. The transaction includes the issuance of contingent value rights (CVRs) to Neuphoria stockholders linked to future milestone payments. Concurrently, Scancell is pursuing a financing package including a $39.1 million private placement, a $12.0 million UK placing, a $3.0 million retail offer, and a $25 million debt facility from BlackRock. The merger is expected to complete in late Q4 2026 and includes a planned 10:1 share consolidation for Scancell. Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company developing neuropsychiatric disorder therapies.